

27 October 2017

THIS DOCUMENT HAS NOT BEEN PRODUCED BY KBC SECURITIES USA, INC.


QUEST FOR GROWTH

Solid 3Q results

EQUITY INVESTMENT INSTRUMENTS
BELGIUM

CURRENT PRICE €8.72
TARGET PRICE €8.70

HOLD
RATING UNCHANGED



Source: Thomson Reuters Datastream

Bloomberg QFG BB
Reuters QUFG.BR
www.questforgrowth.com

Market Cap €100.5m
Shares outst. 11.5m
Volume (daily) €134,195
Free float 72.9%

Next corporate event

Results FY17: 25 January 2018

(€m)	2014	2015	2016
Net result	8.7	37.9	
Adj. net result	8.7	37.9	
Basic EPS (€)	0.76	3.29	
ROE	7.9%	34.5%	
Adj. eq. value	10.28	10.81	
Premium/disc.	26.0%	-5.5%	
DPS (€)	0.72	3.72	0.00
Dividend yield	9.5%	32.6%	

Cédric Duinslaeger

+32 2 429 00 55

cedric.duinslaeger@kbcsecurities.be

Yesterday after market, Quest for Growth reported a profit of €27.8m over the first 9 months of 2017 (vs. €3.7m 9M16). NAV per share stood at €10.74 per end September (representing a 21% discount), as compared to an NAV per share of €8.91 per end December last year.

News:

We saw a general stock market uptake in 3Q17, as shown by the STOXX Europe 600 Net Return Index that went up 9.9% since the start of the year and the STOXX Europe Small 200 gained 15.5% in the same period.

Listed Portfolio:

Gross performance has been 22% since YE16, with Technotrans being up 120%, TKH, Nexus, Pharmagest, Kingspan, USU Software and Norma Group bringing in returns of 40+%. Portfolio losses were seen in Kiadis; Axway and Bertrandt.

In Q3, QfG added Stratec Biomedical to its portfolio (German medical analysis systems) and took profit on shares that had risen sharply (such as Umicore and Technotrans). Positions were increased in CEWE, EVS and Aures.

Unlisted Portfolio:

QfG made an investment of €0.5m, in a JV with ICT Arkiv, in Sensolus (IoT).

VC Funds:

As mentioned ICT Arkiv invested in Sensolus and also Arkite (Virtual assistant in the processing industry). Capricorn Sustainable Chemistry Fund invested in Virovet (developer of vaccins/anti-viral drugs for cattle).

Our View:

The quarterly result is never a surprise: Quest communicates its NAV updates on a monthly basis, hence disclosing indirectly its realised result.

We see a continuation of good performance, driven by strong markets, resulting in an overall NAV increase of approximately 20% since the start of the year.

Conclusion:

Based on yesterday's closing prices, we estimate NAV p.s. at €10.77, hovering 19% above the current stock price of €8.72 (2Y hist. avg. of 16.22%).

We feel comfortable with our Hold recommendation and €8.7 p.s. target price.